Our commitment to innovation in cancer care

Severyne lives with a chronic cancer and chooses hope over fear. She looks to the positive side of her journey — meeting new people and cherishing the sweet moments in her life.

Lorena lives with lung cancer and was told she only had six months to live. Hear about her journey and her search for healing.

See how we’re working to address health disparities to serve more patients with serious disease.

Nick Botwood, senior vice president of Oncology Medical, and Ridwaan Jhetam, senior vice president of Hematology Medical, discuss how Bristol Myers Squibb has built a diverse portfolio to address the unique needs of patients.

Teri Foy, PhD, senior vice president, Research and Early Development Immuno-Oncology and Cell Therapy, shares how we strive to help patients living with complex diseases by drawing on our experience and learnings to pursue new standards of care across therapeutic areas.

Jonathan Cheng, MD, senior vice president, Head of Oncology Development, details how the use of immunotherapy in earlier stages of cancer may help prevent recurrence and improve outcomes for patients.

Noah Berkowitz, MD, PhD, senior vice president, Hematology Development and Global Drug Development, discusses the importance of progress that improves how people live with blood disorders.

Sabine Maier, MD, Head of Oncology and Clinical Development, shares her perspective on witnessing the development of checkpoint inhibitors and their impact on patient care.

Anne Kerber, senior vice president, head of Cell Therapy Development, reflects on her desire to deliver life-changing treatments to patients and how this led her from the clinic to the world of drug discovery and development.

Our scientists search for transformative treatments using a differentiated research and development framework anchored in causal human biology. 

Dana Walker, MD, MSCE, vice president and Genitourinary (GU) Cancers Development Lead, sheds light on the importance of ongoing GU cancer research, the unmet needs for patients with GU tumors and where we go from here to offer hope to even more people impacted by cancer.

Abderrahim Oukessou, MD, our vice president and Thoracic Cancers Development Lead, sat down with Adam Schoenfeld, MD, medical oncologist, Memorial Sloan Kettering Cancer Center to discuss how the landscape of lung cancer research has transformed in recent years.

Rod Humerickhouse, MD, PhD, vice president of Hematology Development, Multiple Myeloma, and Rosanna Ricafort, MD, vice president, head of Cellular Therapy Clinical Development, share more about our commitment to the multiple myeloma community and continued progress in advancing treatment for every patient living with this disease.

We have only scratched the surface of cell therapy’s potential impact for patients with cancer. Read to discover more about ongoing advancement in this field.

Learn more about how we are developing therapies targeting BCMA by leveraging a number of modalities including cell therapies, antibody-drug conjugates and immune cell engagers.

Read about how we’re discovering new methods for overcoming cancer drug resistance.

Hear from researchers harnessing cell’s own machinery to degrade several new classes of proteins that were previously considered “undruggable.”